GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Cash Conversion Cycle

Cadence Pharmaceuticals, (FRA:QEW) Cash Conversion Cycle : 33.75 (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cadence Pharmaceuticals,'s Days Sales Outstanding for the three months ended in Dec. 2013 was 23.55.
Cadence Pharmaceuticals,'s Days Inventory for the three months ended in Dec. 2013 was 58.83.
Cadence Pharmaceuticals,'s Days Payable for the three months ended in Dec. 2013 was 48.63.
Therefore, Cadence Pharmaceuticals,'s Cash Conversion Cycle (CCC) for the three months ended in Dec. 2013 was 33.75.


Cadence Pharmaceuticals, Cash Conversion Cycle Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Cash Conversion Cycle Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -30.10 16.99 33.43

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.01 34.35 32.40 33.36 33.75

Competitive Comparison of Cadence Pharmaceuticals,'s Cash Conversion Cycle

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Cash Conversion Cycle falls into.



Cadence Pharmaceuticals, Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cadence Pharmaceuticals,'s Cash Conversion Cycle for the fiscal year that ended in Dec. 2013 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=25.49+74.15-66.21
=33.43

Cadence Pharmaceuticals,'s Cash Conversion Cycle for the quarter that ended in Dec. 2013 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=23.55+58.83-48.63
=33.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadence Pharmaceuticals,  (FRA:QEW) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cadence Pharmaceuticals, Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines